Imaging proliferation of 18F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer

2012 ◽  
Vol 39 (8) ◽  
pp. 1289-1296 ◽  
Author(s):  
Wenfeng Yang ◽  
Yongming Zhang ◽  
Zheng Fu ◽  
Xiaorong Sun ◽  
Dianbin Mu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Microvessel Density ◽  
Small Cell ◽  
Tumour Tissue ◽  
Small Cell Lung ◽  
Flt Pet ◽  
Pet Ct

FLT-PET/CT in Non-Small Cell Lung Cancer Treated With SBRT- A Pilot Study

2022 ◽  
Vol 112 (2) ◽  
pp. e5-e6
Author(s):  
S.C. Lewis ◽  
A.J. Hope ◽  
M. Chan ◽  
J. Weiss ◽  
H. Raziee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pilot Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Flt Pet ◽  
Pet Ct

scholarly journals Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy

BJR|Open ◽  
2019 ◽  
Vol 1 (1) ◽  
pp. 20190029
Author(s):  
Dominic Carlin ◽  
Alexander Weller ◽  
Gem Kramer ◽  
Yan Liu ◽  
John C Waterton ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumour Necrosis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Flt Pet ◽  
Pet Ct ◽  
Viable Tumour

Objective: To correlate changes in the apparent diffusion coefficient (ADC) from diffusion-weighted (DW)-MRI and standardised uptake value (SUV) from fluorothymidine (18FLT)-PET/CT with histopathological estimates of response in patients with non-small cell lung cancer (NSCLC) treated with neoadjuvant chemotherapy and track longitudinal changes in these biomarkers in a multicentre, multivendor setting. Methods: 14 patients with operable NSCLC recruited to a prospective, multicentre imaging trial (EORTC-1217) were treated with platinum-based neoadjuvant chemotherapy. 13 patients had DW-MRI and FLT-PET/CT at baseline (10 had both), 12 were re-imaged at Day 14 (eight dual-modality) and nine after completing chemotherapy, immediately before surgery (six dual-modality). Surgical specimens (haematoxylin-eosin and Ki67 stained) estimated the percentage of residual viable tumour/necrosis and proliferation index. Results: Despite the small numbers,significant findings were possible. ADCmedian increased (p < 0.001) and SUVmean decreased (p < 0.001) significantly between baseline and Day 14; changes between Day 14 and surgery were less marked. All responding tumours (>30% reduction in unidimensional measurement pre-surgery), showed an increase at Day 14 in ADC75th centile and reduction in total lesion proliferation (SUVmean x proliferative volume) greater than established measurement variability. Change in imaging biomarkers did not correlate with histological response (residual viable tumour, necrosis). Conclusion: Changes in ADC and FLT-SUV following neoadjuvant chemotherapy in NSCLC were measurable by Day 14 and preceded changes in unidimensional size but did not correlate with histopathological response. However, the magnitude of the changes and their utility in predicting (non-) response (tumour size/clinical outcome) remains to be established. Advances in knowledge: During treatment, ADC increase precedes size reductions, but does not reflect histopathological necrosis.

scholarly journals Efficacy of 18F-FDG and 18F-FLT PET/CT for Assessment of Chemoradiotherapy in Patient with Non-Small Cell Lung Cancer (Clinical Observation)

2017 ◽  
pp. 53-56
Author(s):  
N. A. Meshcheryakova ◽  
M. B. Dolgushin ◽  
T. N. Borisova ◽  
M. M. Davydov ◽  
K. K. Laktionov
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Observation ◽  
Early Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Flt Pet ◽  
Pet Ct ◽  
18F Fdg

PET/CT offers the most advanced possibilities for visualization of non-small cell lung cancer (NSCLC) nowadays. 18F-FDG PET/CT plays a significant role in staging of NSCLC, choosing of treatment strategy, planning of radiation therapy and evaluation of its efficacy. Clinical observation of the patient with non-small cell lung cancer with response assessments by 18F-FDG and 18FFLT PET/CT during the course of chemoirradiation is demonstrated. There was a correlation between 18F-FDG and 18F-FLT PET/CT with advantage of 18F-FLT PET/CT for early response evaluation. The combination of 18F-FDG and 18FFLT PET/CT will be helpful to personalize chemoirradiation and to predict response more accurately. The presented clinical case demonstrated the possibilities of 18F-FDG and 18F-FLT PET/CT for assessment of treatment efficacy in patient with non-small cell lung cancer.

Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer

2010 ◽  
Vol 37 (7) ◽  
pp. 1291-1299 ◽  
Author(s):  
Wenfeng Yang ◽  
Yongming Zhang ◽  
Zheng Fu ◽  
Jinming Yu ◽  
Xiaorong Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Small Cell ◽  
Small Cell Lung ◽  
Flt Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Predictive value of 3′-deoxy-3′-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer

2021 ◽  
Vol 9 (7) ◽  
pp. e003079
Author(s):  
Masayuki Sato ◽  
Yukihiro Umeda ◽  
Tetsuya Tsujikawa ◽  
Tetsuya Mori ◽  
Miwa Morikawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Initiation ◽  
Early Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Flt Pet ◽  
Programmed Death ◽  
Programmed Death 1

BackgroundAnti-programmed death-1 (anti-PD-1) therapy has shown clinical success in patients with advanced non-small cell lung cancer (NSCLC). However, it is difficult to evaluate the early response to anti-PD-1 therapy. We determined whether changes in 3′-deoxy-3′-[18F]-fluorothymidine (18F-FLT) PET parameters before and soon after treatment initiation predicted the therapeutic effect of anti-PD-1 antibody.MethodsTwenty-six patients with advanced NSCLC treated with anti-PD-1 antibody were enrolled prospectively and underwent 18F-FLT PET before and at 2 and 6 weeks after treatment initiation. Changes in maximal standardized uptake value (ΔSUVmax), proliferative tumor volume (ΔPTV) and total lesion proliferation (ΔTLP) of the lesions were calculated and evaluated for their associations with the clinical response to therapy.ResultsThe disease control rate was 64%. Patients with non-progressive disease (non-PD) had significantly decreased TLP at 2 weeks, and decreased SUVmax, PTV, and TLP at 6 weeks, compared with those with PD, while three of eight (37.5%) patients who responded had increased TLP from baseline at 2 weeks (ie, pseudoprogression). Among the parameters that changed between baseline and 2 weeks, ΔPTV0-2 and ΔTLP0-2 had the highest accuracy (76.0%) to predict PD. Among the parameters that changed between baseline and 6 weeks, ΔSUVmax0-6, ΔPTV0-6 and ΔTLP0-6 had the highest accuracy (90.9%) to predict PD. ΔTLP0-2 (≥60%, HR 3.41, 95% CI 1.34–8.65, p=0.010) and ΔTLP0-6 (≥50%, HR 31.4, 95% CI 3.55 to 276.7, p=0.0019) were indicators of shorter progression-free survival.ConclusionsChanges in 18F-FLT PET parameters may have value as an early predictive biomarker for the response to anti-PD-1 therapy in patients with NSCLC. However, it should be noted that pseudoprogression was observed in 18F-FLT PET imaging at 2 weeks after treatment initiation.Trial registration numberjRCTs051180147.

Sign in / Sign up

Export Citation Format

Share Document